Sacramento, CA – Senator Ling Ling Chang (R-Diamond Bar) introduced SR 88, calling on the federal government to move United States medical supply chains away from China and create incentives to produce a greater share of pharmaceuticals in the United States.
“The COVID-19 pandemic has underscored the vulnerability of California and the United States with respect to the consolidation of medical supply manufacturing in China,” said Senator Chang. “We must diversify. This overdependence on another nation for personal protective equipment and pharmaceuticals cannot continue. It wreaks havoc on public health and poses a significant risk to our national security.”
The U.S. market is dependent on Chinese pharmaceuticals for 97 percent of antibiotics, 90 percent of vitamin C, and 91 percent of hydrocortisone.
The largest single expenditure by the State of California during the COVID-19 pandemic amounted to almost $1 billion in medical grade face masks from China, who supplied half of the global market in 2018.